We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Chugai has the positive phase 3 data it needs to file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, next year.